Vertex Pharmaceuticals Incorporated (VRTX) PS Ratio: 9.14
Is Vertex Pharmaceuticals Incorporated’s P/S ratio high or low?
Vertex Pharmaceuticals Incorporated's P/S ratio of 9.14 is in line with its 5-year average of 9.74, around the middle of its 5-year range (6.61–12.97).
The P/S ratio for Vertex Pharmaceuticals Incorporated (VRTX) is 9.14 as of Wednesday, June 10, 2026. It is below its 12-month average by 5.59% (9.68).
VRTX PS Ratio Chart
VRTX Average PS Ratio Chart
VRTX Current vs Average PS Ratio Chart
VRTX PS Ratio Metrics
PS RATIO
9.14
PS RATIO AVG TTM
9.68
PS RATIO AVG 3Y
10.54
PS RATIO AVG 5Y
9.74
PS RATIO AVG 10Y
12.21
PS RATIO AVG 15Y
15.66
PS RATIO AVG 20Y
21.13
CURRENT VS TTM AVG
-5.59%
CURRENT VS 3Y AVG
-13.25%
CURRENT VS 5Y AVG
-6.14%
CURRENT VS 10Y AVG
-25.13%
CURRENT VS 15Y AVG
-41.65%
CURRENT VS 20Y AVG
-56.74%
VRTX Competitors' PS Ratio
| NAME | MARKET CAP | PS RATIO | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| Vertex Pharmaceuticals Incorporated (VRTX) | $110.77B | 9.14 | 9.68 | 10.54 | 9.74 |
| Bristol-Myers Squibb Company (BMY) | $114.14B | 2.36 | 2.21 | 2.31 | 2.70 |
| Medtronic plc (MDT) | $103.04B | 2.84 | 3.42 | 3.42 | 3.78 |
| CVS Health Corporation (CVS) | $125.16B | 0.31 | 0.25 | 0.24 | 0.31 |
| Danaher Corporation (DHR) | $130.25B | 5.29 | 6.02 | 6.59 | 6.43 |
| Elevance Health Inc. (ELV) | $87.43B | 0.44 | 0.39 | 0.55 | 0.64 |
| Cigna Corporation (CI) | $78.25B | 0.28 | 0.29 | 0.39 | 0.42 |
| Pfizer Inc. (PFE) | $146.36B | 2.32 | 2.32 | 2.45 | 2.86 |
| Intuitive Surgical, Inc. (ISRG) | $146.44B | 14.07 | 18.73 | 19.88 | 19.01 |
| Gilead Sciences, Inc. (GILD) | $151.21B | 5.13 | 5.41 | 4.32 | 3.91 |
P/S vs. its own history
At 9.14, P/S is cheaper than usual — richer than 17% of its 20-year range.
20-year low
4.57
median
14.76
20-year high
85.34
Sales Valuation
P/S Ratio
9.14
Market Cap / Annual Revenue
Vertex Pharmaceuticals Incorporated PS Ratio Formula & Definition
PS Ratio = Market Cap / Revenue (TTM)
The price-to-sales ratio compares market capitalization to trailing revenue. It is useful for valuing companies with little or no earnings.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
Vertex Pharmaceuticals Incorporated PS Ratio FAQ
- What is the P/S ratio for Vertex Pharmaceuticals Incorporated (VRTX)?
- The P/S ratio for VRTX stock is 9.14.
- Is Vertex Pharmaceuticals Incorporated's P/S ratio high or low?
- Vertex Pharmaceuticals Incorporated's P/S ratio of 9.14 is in line with its 5-year average of 9.74, around the middle of its 5-year range (6.61–12.97).
- What is the TTM average P/S ratio for Vertex Pharmaceuticals Incorporated (VRTX)?
- The TTM average P/S ratio for VRTX stock is 9.68.
- What is the 3Y average P/S ratio for Vertex Pharmaceuticals Incorporated (VRTX)?
- The 3Y average P/S ratio for VRTX stock is 10.54.
- What is the 5Y average P/S ratio for Vertex Pharmaceuticals Incorporated (VRTX)?
- The 5Y average P/S ratio for VRTX stock is 9.74.
- What is the 10Y average P/S ratio for Vertex Pharmaceuticals Incorporated (VRTX)?
- The 10Y average P/S ratio for VRTX stock is 12.21.
- What is the 15Y average P/S ratio for Vertex Pharmaceuticals Incorporated (VRTX)?
- The 15Y average P/S ratio for VRTX stock is 15.66.
- What is the 20Y average P/S ratio for Vertex Pharmaceuticals Incorporated (VRTX)?
- The 20Y average P/S ratio for VRTX stock is 21.13.
Vertex Pharmaceuticals Incorporated PS Ratio History
| DATE | PS RATIO |
|---|---|
| 2026-06-10 | 9.14 |
| 2026-06-09 | 9.32 |
| 2026-06-08 | 9.26 |
| 2026-06-05 | 9.34 |
| 2026-06-04 | 9.24 |
| 2026-06-03 | 8.96 |
| 2026-06-02 | 8.89 |
| 2026-06-01 | 9.17 |
| 2026-05-29 | 9.36 |
| 2026-05-28 | 9.37 |
| 2026-05-27 | 9.14 |
| 2026-05-26 | 9.12 |
| 2026-05-22 | 9.09 |
| 2026-05-21 | 9.07 |
| 2026-05-20 | 9.00 |
| 2026-05-19 | 9.08 |
| 2026-05-18 | 9.13 |
| 2026-05-15 | 9.14 |
| 2026-05-14 | 9.42 |
| 2026-05-13 | 9.48 |
| 2026-05-12 | 9.38 |
| 2026-05-11 | 9.10 |
| 2026-05-08 | 8.99 |
| 2026-05-07 | 8.89 |
| 2026-05-06 | 8.94 |
| 2026-05-05 | 8.87 |
| 2026-05-04 | 9.14 |
| 2026-05-01 | 9.02 |
| 2026-04-30 | 9.09 |
| 2026-04-29 | 9.00 |
| 2026-04-28 | 9.15 |
| 2026-04-27 | 9.06 |
| 2026-04-24 | 9.15 |
| 2026-04-23 | 9.26 |
| 2026-04-22 | 9.31 |
| 2026-04-21 | 9.29 |
| 2026-04-20 | 9.34 |
| 2026-04-17 | 9.39 |
| 2026-04-16 | 9.27 |
| 2026-04-15 | 9.40 |
| 2026-04-14 | 9.45 |
| 2026-04-13 | 9.36 |
| 2026-04-10 | 9.28 |
| 2026-04-09 | 9.50 |
| 2026-04-08 | 9.44 |
| 2026-04-07 | 9.19 |
| 2026-04-06 | 9.24 |
| 2026-04-02 | 9.33 |
| 2026-04-01 | 9.51 |
| 2026-03-31 | 9.50 |
| 2026-03-30 | 9.43 |
| 2026-03-27 | 9.21 |
| 2026-03-26 | 9.65 |
| 2026-03-25 | 9.68 |
| 2026-03-24 | 9.54 |
| 2026-03-23 | 9.60 |
| 2026-03-20 | 9.66 |
| 2026-03-19 | 9.74 |
| 2026-03-18 | 9.61 |
| 2026-03-17 | 9.84 |
| 2026-03-16 | 9.92 |
| 2026-03-13 | 9.98 |
| 2026-03-12 | 10.17 |
| 2026-03-11 | 10.47 |
| 2026-03-10 | 10.62 |
| 2026-03-09 | 9.80 |
| 2026-03-06 | 9.72 |
| 2026-03-05 | 9.80 |
| 2026-03-04 | 10.17 |
| 2026-03-03 | 10.09 |
| 2026-03-02 | 10.34 |
| 2026-02-27 | 10.57 |
| 2026-02-26 | 10.21 |
| 2026-02-25 | 10.28 |
| 2026-02-24 | 10.37 |
| 2026-02-23 | 10.23 |
| 2026-02-20 | 10.15 |
| 2026-02-19 | 9.98 |
| 2026-02-18 | 10.01 |
| 2026-02-17 | 10.15 |
| 2026-02-13 | 10.46 |
| 2026-02-12 | 10.22 |
| 2026-02-11 | 10.13 |
| 2026-02-10 | 10.18 |
| 2026-02-09 | 10.35 |
| 2026-02-06 | 10.50 |
| 2026-02-05 | 10.08 |
| 2026-02-04 | 10.34 |
| 2026-02-03 | 10.23 |
| 2026-02-02 | 10.37 |
| 2026-01-30 | 10.33 |
| 2026-01-29 | 10.45 |
| 2026-01-28 | 10.50 |
| 2026-01-27 | 10.42 |
| 2026-01-26 | 10.48 |
| 2026-01-23 | 10.29 |
| 2026-01-22 | 10.27 |
| 2026-01-21 | 10.13 |
| 2026-01-20 | 9.71 |
| 2026-01-16 | 9.70 |
| 2026-01-15 | 9.64 |
| 2026-01-14 | 9.88 |
| 2026-01-13 | 9.99 |
| 2026-01-12 | 10.12 |
| 2026-01-09 | 10.19 |
| 2026-01-08 | 10.32 |
| 2026-01-07 | 10.64 |
| 2026-01-06 | 10.29 |
| 2026-01-05 | 9.86 |
| 2026-01-02 | 9.93 |
| 2025-12-31 | 9.96 |
| 2025-12-30 | 9.97 |
| 2025-12-29 | 10.10 |
| 2025-12-26 | 10.17 |
| 2025-12-24 | 10.17 |
| 2025-12-23 | 10.09 |
| 2025-12-22 | 10.11 |
| 2025-12-19 | 10.02 |
| 2025-12-18 | 9.83 |
| 2025-12-17 | 9.88 |
| 2025-12-16 | 10.00 |
| 2025-12-15 | 10.01 |
| 2025-12-12 | 9.93 |
| 2025-12-11 | 9.80 |
| 2025-12-10 | 9.77 |
| 2025-12-09 | 9.60 |
| 2025-12-08 | 9.71 |
| 2025-12-05 | 10.01 |
| 2025-12-04 | 10.05 |
| 2025-12-03 | 10.18 |
| 2025-12-02 | 9.52 |
| 2025-12-01 | 9.35 |
| 2025-11-28 | 9.53 |
| 2025-11-26 | 9.50 |
| 2025-11-25 | 9.44 |
| 2025-11-24 | 9.32 |
| 2025-11-21 | 9.38 |
| 2025-11-20 | 9.28 |
| 2025-11-19 | 9.25 |
| 2025-11-18 | 9.57 |
| 2025-11-17 | 9.54 |
| 2025-11-14 | 9.61 |
| 2025-11-13 | 9.55 |
| 2025-11-12 | 9.54 |
| 2025-11-11 | 9.43 |
| 2025-11-10 | 9.26 |
| 2025-11-07 | 9.00 |
| 2025-11-06 | 9.15 |
| 2025-11-05 | 9.16 |
| 2025-11-04 | 9.27 |
| 2025-11-03 | 9.66 |
| 2025-10-31 | 9.65 |
| 2025-10-30 | 9.52 |
| 2025-10-29 | 9.46 |
| 2025-10-28 | 9.58 |
| 2025-10-27 | 9.53 |
| 2025-10-24 | 9.55 |
| 2025-10-23 | 9.58 |
| 2025-10-22 | 9.67 |
| 2025-10-21 | 9.66 |
| 2025-10-20 | 9.50 |
| 2025-10-17 | 9.45 |
| 2025-10-16 | 9.26 |
| 2025-10-15 | 9.25 |
| 2025-10-14 | 9.35 |
| 2025-10-13 | 9.24 |
| 2025-10-10 | 9.25 |
| 2025-10-09 | 9.41 |
| 2025-10-08 | 9.55 |
| 2025-10-07 | 9.30 |
| 2025-10-06 | 9.14 |
| 2025-10-03 | 9.14 |
| 2025-10-02 | 9.27 |
| 2025-10-01 | 9.16 |
| 2025-09-30 | 8.88 |
| 2025-09-29 | 8.96 |
| 2025-09-26 | 8.75 |
| 2025-09-25 | 8.66 |
| 2025-09-24 | 8.54 |
| 2025-09-23 | 8.61 |
| 2025-09-22 | 8.69 |
| 2025-09-19 | 8.69 |
| 2025-09-18 | 8.78 |
| 2025-09-17 | 8.78 |
| 2025-09-16 | 8.87 |
| 2025-09-15 | 8.92 |
| 2025-09-12 | 8.95 |
| 2025-09-11 | 9.01 |
| 2025-09-10 | 8.81 |
| 2025-09-09 | 8.99 |
| 2025-09-08 | 8.96 |
| 2025-09-05 | 8.98 |
| 2025-09-04 | 9.00 |
| 2025-09-03 | 8.99 |
| 2025-09-02 | 9.09 |
| 2025-08-29 | 8.87 |
| 2025-08-28 | 8.89 |
| 2025-08-27 | 8.82 |
| 2025-08-26 | 8.78 |
| 2025-08-25 | 8.82 |
| 2025-08-22 | 8.96 |
| 2025-08-21 | 9.01 |
| 2025-08-20 | 8.94 |
| 2025-08-19 | 8.86 |
| 2025-08-18 | 8.84 |
| 2025-08-15 | 8.91 |
| 2025-08-14 | 8.85 |
| 2025-08-13 | 8.98 |
| 2025-08-12 | 8.79 |
| 2025-08-11 | 8.49 |
| 2025-08-08 | 8.31 |
| 2025-08-07 | 8.52 |
| 2025-08-06 | 8.74 |
| 2025-08-05 | 8.50 |
| 2025-08-04 | 11.04 |
| 2025-08-01 | 10.80 |
| 2025-07-31 | 10.68 |
| 2025-07-30 | 10.97 |
| 2025-07-29 | 10.95 |
| 2025-07-28 | 10.77 |
| 2025-07-25 | 10.98 |
| 2025-07-24 | 11.04 |
| 2025-07-23 | 11.15 |
| 2025-07-22 | 10.99 |
| 2025-07-21 | 10.72 |
| 2025-07-18 | 10.75 |
| 2025-07-17 | 10.83 |
| 2025-07-16 | 10.98 |
| 2025-07-15 | 10.85 |
| 2025-07-14 | 11.04 |
| 2025-07-11 | 10.96 |
| 2025-07-10 | 11.21 |
| 2025-07-09 | 11.20 |
| 2025-07-08 | 10.90 |
| 2025-07-07 | 10.74 |
| 2025-07-03 | 10.75 |
| 2025-07-02 | 10.68 |
| 2025-07-01 | 10.57 |
| 2025-06-30 | 10.41 |
| 2025-06-27 | 10.32 |
| 2025-06-26 | 10.37 |
| 2025-06-25 | 10.42 |
| 2025-06-24 | 10.53 |
| 2025-06-23 | 10.37 |
| 2025-06-20 | 10.31 |
| 2025-06-18 | 10.48 |
| 2025-06-17 | 10.33 |
| 2025-06-16 | 10.54 |
| 2025-06-13 | 10.65 |
| 2025-06-12 | 10.76 |
| 2025-06-11 | 10.58 |
| 2025-06-10 | 10.56 |
| 2025-06-09 | 10.43 |
| 2025-06-06 | 10.53 |
| 2025-06-05 | 10.38 |
| 2025-06-04 | 10.42 |
| 2025-06-03 | 10.44 |
| 2025-06-02 | 10.41 |
| 2025-05-30 | 10.33 |
| 2025-05-29 | 10.45 |
Showing the most recent 260 of 5,031 data points. The chart above shows the full history.
Related Metrics
About Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals Incorporated is a leading biotechnology firm primarily focused on the discovery, advancement, and marketing of innovative treatments, particularly for cystic fibrosis (CF). The company offers a range of approved medications for CF patients, including SYMDEKO/SYMKEVI, ORKAMBI, and KALYDECO, which target specific mutations within the cystic fibrosis transmembrane conductance regulator gene. Additionally, they provide TRIKAFTA for individuals with CF aged six years and older who possess at least one F508del mutation. Beyond its established CF therapies, Vertex maintains a robust and diverse clinical pipeline. This includes VX-864, currently in Phase 2 for alpha-1 antitrypsin (AAT) deficiency; VX-147, also in Phase 2, addressing APOL1-mediated focal segmental glomerulosclerosis (FSGS) and other serious kidney conditions; VX-880, a potential treatment for Type 1 Diabetes undergoing Phase 1/2 trials; VX-548, a NaV1.8 inhibitor in Phase 2 for various forms of acute, neuropathic, and musculoskeletal pain; and CTX001, which is in Phase 3 development for severe sickle cell disease (SCD) and transfusion-dependent beta-thalassemia (TDT). The company distributes its pharmaceutical products through specialty pharmacies and distributors across the United States, while international sales are facilitated via a network of specialty distributors, retail chains, hospitals, and clinics. Vertex also engages in numerous strategic collaborations with partners such as Affinia Therapeutics, Arbor Biotechnologies, CRISPR Therapeutics, Kymera Therapeutics, Mammoth Biosciences, Moderna, Obsidian Therapeutics, Skyhawk Therapeutics, Ribometrix, Genomics plc, Merck KGaA, and X-Chem. Established in 1989, Vertex Pharmaceuticals is headquartered in Boston, Massachusetts.
- Sector
- Healthcare
- Industry
- Biotechnology
- CEO
- Reshma Kewalramani